Unimpeded skin carcinogenesis in K14-HPV16 transgenic mice deficient for plasminogen activator inhibitor

International Journal of Cancer

Volumn 128, Issue 2, 2011, Pages 283-293

  Masset, Anne ^a   Maillard, Catherine ^a   Sounni, Nor Eddine ^a   Jacobs, Nathalie ^b   Bruyére, Françoise ^a   Delvenne, Philippe ^b   Tacke, Marlene ^c   Reinheckel, Thomas ^c   Foidart, Jean Michel ^a   Coussens, Lisa M ^d   Noaël, Agnès ^a  

^a Laboratory of Biology of Tumor and Development   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

^c UNIVERSITY OF FREIBURG   (Germany)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

angiogenesis; K14 HPV16; lymphangiogenesis; plasminogen activator

Indexed keywords

MESSENGER RNA; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER GROWTH; CANCER STAGING; CELL PROLIFERATION; CONTROLLED STUDY; EPIDERMIS HYPERPLASIA; GENE DELETION; GENE EXPRESSION REGULATION; GENE SWITCHING; GENOTYPE; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; INFLAMMATORY INFILTRATE; KERATINOCYTE; LYMPHANGIOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; QUANTITATIVE ANALYSIS; SKIN CARCINOGENESIS; SQUAMOUS CELL CARCINOMA; TRANSGENIC MOUSE; TUMOR VASCULARIZATION;

ANIMALS; HUMAN PAPILLOMAVIRUS 16; KERATIN-14; LYMPHANGIOGENESIS; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; PLASMINOGEN ACTIVATOR INHIBITOR 1; PRECANCEROUS CONDITIONS; SKIN NEOPLASMS;

EID: 78649560431     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25326     Document Type: Article

References (61)

1. Binder BR, Mihaly J,. The plasminogen activator inhibitor "paradox" in cancer. Immunol Lett 2008; 118: 116-24.
2. Andreasen PA, Egelund R, Petersen HH,. The plasminogen activation system in tumor growth, invasion, and metastasis. Cell Mol Life Sci 2000; 57: 25-40.
3. Rakic JM, Maillard C, Jost M, Bajou K, Masson V, Devy L, Lambert V, Foidart JM, Noel A,. Role of plasminogen activator-plasmin system in tumor angiogenesis. Cell Mol Life Sci 2003; 60: 463-73.
4. Duffy MJ,. Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level I evidence studies. Clin Chem 2002; 48: 1194-7.
5. Wilkins-Port CE, Higgins CE, Freytag J, Higgins SP, Carlson JA, Higgins PJ,. PAI-1 is a critical upstream regulator of the TGF-beta 1/EGF-induced invasive phenotype in mutant p53 human cutaneous squamous cell carcinoma. J Biomed Biotechnol 2007; 2007: 85208.
6. Hildenbrand R, Schaaf A,. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion. Int J Oncol 2009; 34: 15-23.
7. Pedersen TX, Pennington CJ, Almholt K, Christensen IJ, Nielsen BS, Edwards DR, Romer J, Dano K, Johnsen M,. Extracellular protease mRNAs are predominantly expressed in the stromal areas of microdissected mouse breast carcinomas. Carcinogenesis 2005; 26: 1233-40.
8. van Hinsbergh VW, van den Berg EA, Fiers W, Dooijewaard G,. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood 1990; 75: 1991-8.
9. Cho SH, Tam SW, Demissie-Sanders S, Filler SA, Oh CK,. Production of plasminogen activator inhibitor-1 by human mast cells and its possible role in asthma. J Immunol 2000; 165: 3154-61.
10. Lund LR, Riccio A, Andreasen PA, Nielsen LS, Kristensen P, Laiho M, Saksela O, Blasi F, Dano K,. Transforming growth factor-beta is a strong and fast acting positive regulator of the level of type-1 plasminogen activator inhibitor mRNA in WI-38 human lung fibroblasts. EMBO J 1987; 6: 1281-6.
11. Offersen BV, Nielsen BS, Hoyer-Hansen G, Rank F, Hamilton-Dutoit S, Overgaard J, Andreasen PA,. The myofibroblast is the predominant plasminogen activator inhibitor-1-expressing cell type in human breast carcinomas. Am J Pathol 2003; 163: 1887-99.
12. Degryse B, Neels JG, Czekay RP, Aertgeerts K, Kamikubo Y, Loskutoff DJ,. The low density lipoprotein receptor-related protein is a motogenic receptor for plasminogen activator inhibitor-1. J Biol Chem 2004; 279: 22595-604.
13. Kamikubo Y, Neels JG, Degryse B,. Vitronectin inhibits plasminogen activator inhibitor-1-induced signalling and chemotaxis by blocking plasminogen activator inhibitor-1 binding to the low-density lipoprotein receptor-related protein. Int J Biochem Cell Biol 2009; 41: 578-85.
14. Czekay RP, Aertgeerts K, Curriden SA, Loskutoff DJ,. Plasminogen activator inhibitor-1 detaches cells from extracellular matrices by inactivating integrins. J Cell Biol 2003; 160: 781-91.
15. Schar CR, Jensen JK, Christensen A, Blouse GE, Andreasen PA, Peterson CB,. Characterization of a site on PAI-1 that binds to vitronectin outside of the somatomedin B domain. J Biol Chem 2008; 283: 28487-96.
16. Chen YB, Budd RC, Kelm RJ, Sobel BE, Schneider DJ,. Augmentation of proliferation of vascular smooth muscle cells by plasminogen activator inhibitor type 1. Arteriosclerosis Thromb Vasc Biol 2006; 26: 1777-83.
17. Ploplis VA, Balsara R, Sandoval-Cooper MJ, Yin ZJ, Batten J, Modi N, Gadoua D, Donahue D, Martin JA, Castellino FJ,. Enhanced in vitro proliferation of aortic endothelial cells from plasminogen activator inhibitor-1-deficient mice. J Biol Chem 2004; 279: 6143-51.
18. Bajou K, Peng H, Laug WE, Maillard C, Noel A, Foidart JM, Martial JA, DeClerck YA,. Plasminogen activator inhibitor-1 protects endothelial cells from FasL-mediated apoptosis. Cancer Cell 2008; 14: 324-34.
19. Noel A, Maillard C, Rocks N, Jost M, Chabottaux V, Sounni NE, Maquoi E, Cataldo D, Foidart JM,. Membrane associated proteases and their inhibitors in tumour angiogenesis. J Clin Pathol 2004; 57: 577-84.
20. Devy L, Blacher S, Grignet-Debrus C, Bajou K, Masson V, Gerard RD, Gils A, Carmeliet G, Carmeliet P, Declerck PJ, Noel A, Foidart JM,. The pro- or antiangiogenic effect of plasminogen activator inhibitor 1 is dose dependent. FASEB J 2002; 16: 147-54.
21. Bajou K, Noel A, Gerard RD, Masson V, Brunner N, Holst-Hansen C, Skobe M, Fusenig NE, Carmeliet P, Collen D, Foidart JM,. Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 1998; 4: 923-8.
22. Gutierrez LS, Schulman A, Brito-Robinson T, Noria F, Ploplis VA, Castellino FJ,. Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 2000; 60: 5839-47.
23. Leik CE, Su EJ, Nambi P, Crandall DL, Lawrence DA,. Effect of pharmacologic plasminogen activator inhibitor-1 inhibition on cell motility and tumor angiogenesis. J Thromb Haemost 2006; 4: 2710-5.
24. Maillard C, Jost M, Romer MU, Brunner N, Houard X, Lejeune A, Munaut C, Bajou K, Melen L, Dano K, Carmeliet P, Fusenig NE, et al. Host plasminogen activator inhibitor-1 promotes human skin carcinoma progression in a stage-dependent manner. Neoplasia 2005; 7: 57-66.
25. Almholt K, Nielsen BS, Frandsen TL, Brunner N, Dano K, Johnsen M,. Metastasis of transgenic breast cancer in plasminogen activator inhibitor-1 gene-deficient mice. Oncogene 2003; 22: 4389-97.
26. Maillard CM, Bouquet C, Petitjean MM, Mestdagt M, Frau E, Jost M, Masset AM, Opolon PH, Beermann F, Abitbol MM, Foidart JM, Perricaudet MJ, et al. Reduction of brain metastases in plasminogen activator inhibitor-1-deficient mice with transgenic ocular tumors. Carcinogenesis 2008; 29: 2236-42.
27. van Kempen LCL, de Visser KE, Coussens LM,. Inflammation, proteases and cancer. Eur J Cancer 2006; 42: 728-34.
28. Cao C, Lawrence DA, Li Y, Von Arnim CA, Herz J, Su EJ, Makarova A, Hyman BT, Strickland DK, Zhang L,. Endocytic receptor LRP together with tPA and PAI-1 coordinates Mac-1-dependent macrophage migration. EMBO J 2006; 25: 1860-70.
29. Kwak SH, Wang XQ, He Q, Fang WF, Mitra S, Bdeir K, Ploplis VA, Xu Z, Idell S, Cines D, Abraham E,. Plasminogen activator inhibitor-1 potentiates LPS-induced neutrophil activation through a JNK-mediated pathway. Thromb Haemost 2006; 95: 829-35.
30. Park YJ, Liu G, Lorne EF, Zhao X, Wang J, Tsuruta Y, Zmijewski J, Abraham E,. PAI-1 inhibits neutrophil efferocytosis. Proc Natl Acad Sci USA 2008; 105: 11784-9.
31. Coussens LM, Hanahan D, Arbeit JM,. Genetic predisposition and parameters of malignant progression in K14-HPV16 transgenic mice. Am J Pathol 1996; 149: 1899-917.
32. van Kempen LCL, Rhee JS, Dehne K, Lee J, Edwards DR, Coussens LM,. Epithelial carcinogenesis: dynamic interplay between neoplastic cells and their microenvironment. Differentiation 2002; 70: 610-23.
33. Coussens LM, Raymond WW, Bergers G, Laig-Webster M, Behrendtsen O, Werb Z, Caughey GH, Hanahan D,. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev 1999; 13: 1382-97.
34. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A,. The history of the angiogenic switch concept. Leukemia 2007; 21: 44-52.
35. Coussens LM, Tinkle CL, Hanahan D, Werb Z,. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000; 103: 481-90.
36. Arbeit JM, Munger K, Howley PM, Hanahan D,. Progressive squamous epithelial neoplasia in K14-human papillomavirus type 16 transgenic mice. J Virol 1994; 68: 4358-68.
37. de Visser KE, Korets LV, Coussens LM,. Early neoplastic progression is complement independent. Neoplasia 2004; 6: 768-76.
38. Cao Y, Zhong W,. Tumor-derived lymphangiogenic factors and lymphatic metastasis. Biomed Pharmacother 2007; 61: 534-39.
39. Cao YH,. Opinion-emerging mechanisms of tumour lymphangiogenesis and lymphatic metastasis. Nat Rev Cancer 2005; 5: 735-43.
40. Eichten A, Hyun WC, Coussens LM,. Distinctive features of anglogenesis and lymphangiogenesis determine their functionality during de novo tumor development. Cancer Res 2007; 67: 5211-20.
41. Junankar SR, Eichten A, Kramer A, de Visser KE, Coussens LM,. Analysis of immune cell infiltrates during squamous carcinoma development. J Investig Dermatol Symp Proc 2006; 11: 36-43.
42. Eichten A, Hyun WC, Coussens LM,. Distinctive features of anglogenesis and lymphangiogenesis determine their functionality during de novo tumor development. Cancer Res 2007; 67: 5211-20.
43. Adams RH, Alitalo K,. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol 2007; 8: 464-78.
44. Bruyere F, Melen-Lamalle L, Blacher S, Roland G, Thiry M, Moons L, Frankenne F, Carmeliet P, Alitalo K, Libert C, Sleeman JP, Foidart JM, et al. Modeling lymphangiogenesis in a three-dimensional culture system. Nat Methods 2008; 5: 431-7.
45. El Solh AA, Bhora M, Pineda L, Aquilina A, Abbetessa L, Berbary E,. Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis. Intensive Care Med 2006; 32: 110-15.
46. Prabhakaran P, Ware LB, White KE, Cross MT, Matthay MA, Olman MA,. Elevated levels of plasminogen activator inhibitor-1 in pulmonary edema fluid are associated with mortality in acute lung injury. Am J Physiol Lung Cell Mol Physiol 2003; 285: L20-L28.
47. Takeshita K, Hayashi M, Iino S, Kondo T, Inden Y, Iwase M, Kojima T, Hirai M, Ito M, Loskutoff DJ, Saito H, Murohara T, et al. Increased expression of plasminogen activator inhibitor-1 in cardiomyocytes contributes to cardiac fibrosis after myocardial infarction. Am J Pathol 2004; 164: 449-56.
48. Andreasen PA,. PAI-1-a potential therapeutic target in cancer. Curr Drug Targets 2007; 8: 1030-41.
49. McMahon B, Kwaan HC,. The plasminogen activator system and cancer. Pathophysiol Haemost Thromb 2008; 36: 184-94.
50. Lambert V, Munaut C, Noel A, Frankenne F, Bajou K, Gerard R, Carmeliet P, Defresne MP, Foidart JM, Rakic JM,. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J 2001; 15: 1021-7.
51. Lund LR, Romer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, Stephens RW, Dano K,. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 1999; 18: 4645-56.
52. Lee CC, Huang TS,. Plasminogen activator inhibitor-1: the expression, biological functions, and effects on tumorigenesis and tumor cell adhesion and migration. J Cancer Mol 2005; 1: 25-36.
53. Bajou K, Masson V, Gerard RD, Schmitt PM, Albert V, Praus M, Lund LR, Frandsen TL, Brunner N, Dano K, Fusenig NE, Weidle U, et al. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J Cell Biol 2001; 152: 777-84.
54. Martin MD, Carter KJ, Jean-Philippe SR, Chang M, Mobashery S, Thiolloy S, Lynch CC, Matrisian LM, Fingleton B,. Effect of ablation or inhibition of stromal matrix metalloproteinase-9 on lung metastasis in a breast cancer model is dependent on genetic background. Cancer Res 2008; 68: 6251-9.
55. Wakabayashi Y, Mao JH, Brown K, Girardi M, Balmain A,. Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature 2007; 445: 761-5.
56. Lifsted T, Le Voyer T, Williams M, Muller W, Klein-Szanto A, Buetow KH, Hunter KW,. Identification of inbred mouse strains harboring genetic modifiers of mammary tumor age of onset and metastatic progression. Int J Cancer 1998; 77: 640-4.
57. Fluck, MM, Schaffhausen BS,. Lessons in signaling and tumorigenesis from polyomavirus middle T antigen. Microbiol Mol Biol Rev 2009; 73: 542-63.
58. Park YG, Zhao X, Lesueur F, Lowy DR, Lancaster M, Pharoah P, Qian X Hunter KW,. Sipa1 is a candidate for underlying the metastasis efficiency modifier locus Mtes1. Nat Genet 2005; 37: 1055-62.
59. Hunter KW, Broman KW, Voyer TL, Lukes L, Cozma D, Debies MT, Rouse J, Welch DR,. Predisposition to efficient mammary tumor metastatic progression is linked to the breast cancer metastasis suppressor gene Brms1. Cancer Res 2001; 61: 8866-72.
60. Jankun J, Aleem AM, Specht Z, Keck RW, Lysiak-Szydlowska W, Selman SH, Skrzypczak-Jankun E,. PAI-1 induces cell detachment, downregulates nucleophosmin (B23) and fortilin (TCTP) in LnCAP prostate cancer cells. Int J Mol Med 2007; 20: 11-20.
61. Balsara RD, Castellino FJ, Ploplis VA,. A novel function of plasminogen activator inhibitor-1 in modulation of the AKT pathway in wild-type and plasminogen activator inhibitor-1-deficient endothelial cells. J Biol Chem 2006; 281: 22527-36.